Suven Life Sciences Limited — Others, 28-05-2025: Corrigendum

Suven Life Sciences has announced a board meeting to consider a preferential issue of up to 6.4 crore convertible warrants at ₹134 each, targeting ₹857.64 Cr. The funds will support clinical development through its overseas subsidiary (₹400 Cr), drug discovery R&D (₹130 Cr), a new R&D centre (₹200 Cr), and general corporate purposes (up to ₹127.64 Cr). Pricing aligns with recent market values and an independent valuation. The company and its promoters maintain a clean compliance record, with no wilful defaults or fugitive economic offender status.